Renal profile of patients treated with elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide fumarate and dolutegravir/abacavir/lamivudine: 120-week results from a real-world cohort.

Sandra Rotea-SalvoAlejandro Martínez-PradedaCarla Fernández-OliveiraVictor Giménez-ArufeVanesa Balboa-BarreiroLuis Margusino-FramiñánÁlvaro Mena-De-CeaPilar Vázquez-RodríguezÁngeles Castro-IglesiasSoledad López-CalvoIsabel Martín-HerranzEnrique Míguez-ReyPurificación Cid-Silva

Published in: European journal of hospital pharmacy : science and practice (2021)

During the follow-up, patients experienced changes that were not clinically relevant in both treatment groups. Differences in renal events were not found.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
hiv infected patients
antiretroviral therapy
peritoneal dialysis
randomized controlled trial
smoking cessation